ImmunityBio(IBRX)
Focus: ImmunityBio is a San Diego-based public biotech company specializing in cellular therapy and immuno-oncology, with a focus on early-to-mid stage clinical programs across multiple cancer indications and infectious diseases.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
74+8 this month
Growing — net +8 jobs in 30d
26 jobs added vs 18 removed. Steady team buildout.
Should You Work at ImmunityBio?
AI assessmentImmunityBio presents a high-risk, high-reward opportunity for scientists and commercial professionals willing to back an early-stage cellular therapy play, but only with clear risk tolerance for cash burn and potential restructuring.
Why Work Here
- Active hiring across 71 open roles with heavy Commercial investment (32 roles), signaling pre-launch or launch-phase preparation for pipeline candidates
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$622K
Pipeline & Clinical Trials
N803 plus Bacillus Calmette-Guerin
Non Muscle Invasive Bladder CancerClinical Trials (1)
NCT05981131Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
N/AHelp build intelligence for ImmunityBio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.